Lilly's Jaypirca (pirtobrutinib) Meets Primary Endpoint in Phase 3 CLL/SLL Trial

Eli Lilly and Company announced positive topline results from the Phase 3 BRUIN CLL-314 clinical trial of Jaypirca (pirtobrutinib), a non-covalent BTK...